News & Events
Keep up with the latest news, insights and events from Norstella and its market-leading brands
In the News
- R&D World
Norstella Launches Atlas, a Biopharma Agentic Platform that Can ‘Train You’
Norstella’s new Atlas platform combines proprietary biopharma data with purpose-built AI agents to help life sciences teams quickly analyze complex information, streamline workflows, and make more informed decisions.
…- The Wall Street Journal
The Race to Come Up With the Next Big Sleep Drug
The article highlights a new generation of sleep drugs that target orexin, a brain chemical responsible for regulating wakefulness. Following the FDA approval of Takeda’s Orzeyful for narcolepsy, companies including Eli Lilly and Alkermes are developing similar treatments that could extend into sleep apnea, fatigue…
- CNBC
AstraZeneca May Buck a Decade of Pharma Strategy to Buy U.S. Scale
AstraZeneca’s reported merger talks with Bristol Myers Squibb highlight the potential for a major pharma deal that could expand AstraZeneca’s U.S. presence, while raising significant questions around integration, growth, and regulatory hurdles.
…- Discover Pharma
Norstella Launches Agentic AI Platform for Biopharma Decision-Making
The article highlights Norstella’s launch of Atlas, an agentic AI platform that combines proprietary life sciences data with purpose-built AI agents to deliver decision-ready insights. Beginning with competitive intelligence, Atlas is designed to produce traceable, actionable outputs in minutes while eventually expanding into areas such…
- PharmaLive
Purpose-Building an AI Offering for Drug Development
The article explores how Norstella developed Atlas, an agentic AI platform designed to turn decades of proprietary life sciences data into actionable insights for drug development. By delivering sourced, contextual and decision-ready outputs, Atlas aims to reduce time spent gathering and analyzing data while helping…
- Drug Discovery World
New Index Reveals Eli Lilly as the Top Ranked Company
The article highlights Norstella’s new Pipeline-to-Patient Productivity Index, which ranks Eli Lilly as the top-performing global biopharma company based on R&D productivity, market access and commercial performance. The findings also reveal growing industry pressures, including rising R&D costs, longer development timelines and slowing pipeline creation,…
- Fierce Biotech
Eli Lilly Tops New Biopharma Ranking on Launch Success, Development Speed
The article highlights Eli Lilly’s rise to the top of Norstella’s inaugural Pipeline-to-Patient Productivity Index, driven by strong drug launches, efficient development timelines and productive R&D. The findings also reveal broader industry challenges, including rising R&D spending, slower pipeline creation and lengthening drug development timelines.
…- R&D World
Recursion Says Its Norstella-Backed Real-Time Simulation Can Expand Trial Eligibility By Up to 40%
The article explores how Recursion is using Norstella’s Citeline data and tools to simulate clinical trials before enrollment begins, helping optimize eligibility criteria and site selection. The approach has expanded modeled patient eligibility by 10%–40% and helped Recursion exceed historical enrollment projections, demonstrating how AI…
- The Wall Street Journal
U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China
The article examines how U.S. biotech companies are becoming more secretive about early-stage research as competition from China intensifies. With Chinese drugmakers able to rapidly develop fast-following therapies, some U.S. companies are limiting conference presentations and investor disclosures to protect their innovations and maintain a…
- Drug Discovery World
How AI Has Revolutionised Clinical Development
The article explores how AI is transforming clinical development by combining advanced technology with real-world data to improve trial planning and decision-making. Norstella’s Suzanne Caruso discusses how becoming “AI-native” can help drug developers navigate complex development timelines and ultimately bring treatments to patients faster.
…- The Wall Street Journal
New Drugs Are Replacing Chemo for Aggressive Breast Cancer
The article highlights new targeted treatments that are reshaping care for aggressive triple-negative breast cancer. Recently approved antibody-drug conjugates Trodelvy and Datroway deliver chemotherapy more directly to tumor cells, reducing disease-progression risk by around 40% compared with traditional chemotherapy and offering new hope for patients…
- PharmaVoice
How Lilly is Defending its GLP Empire
The article examines how Eli Lilly is expanding its GLP portfolio beyond weight loss, using promising clinical data and strategic deals to target new indications. Its efforts span areas such as gastrointestinal disease, sleep apnea and osteoarthritis, positioning the company to strengthen its leadership across…
- PharmaTimes
The Promised Land: Looking to a Brighter Future Must Surely Involve Patient Diversity
This PharmaTimes issue explores key healthcare and pharma trends shaping 2026, including the continued growth of GLP-1 therapies, the importance of patient diversity and ongoing pressures on healthcare budgets. It also examines how these shifts are influencing the industry’s approach to innovation, access and the…
- CNBC
A Hotly Debated Lung Cancer Drug Cut the Risk of Death by 34% in a Late-Stage Trial in China
The article highlights promising Phase 3 results for Akeso’s ivonescimab, which significantly improved survival in patients with advanced squamous non-small cell lung cancer. The findings strengthen the potential of PD-1/VEGF bispecific therapies as a new treatment approach and underscore China’s growing influence in global oncology…
- pharmaphorum
Trustworthy and Novel AI in Clinical Trial Planning, with Kris Kaneta
The article explores how AI can improve clinical trial planning and commercialization by turning robust life sciences data into actionable strategic recommendations. Norstella’s Kris Kaneta also highlights the importance of patient-level data and the challenges that must be addressed to expand AI’s impact across clinical…
- R&D World
Norstella’s AI Bet: Clinical Trials are Often Won or Lost Before the First Patient Enrolls
Norstella is using AI and connected data to help life sciences teams make smarter, higher-confidence decisions before clinical trials begin. By bringing together real-world and proprietary intelligence, Norstella aims to identify potential challenges earlier, optimize trial design and site selection, and ultimately accelerate drug development.
…- Pharmaceutical Commerce
Pharma M&A in 2026: Can the Industry Keep Up the Momentum?
The article examines the outlook for pharma M&A in 2026, as patent expirations and significant revenue growth gaps continue to drive demand for acquisitions. While overall deal value may fall below 2025 levels, companies are expected to pursue fewer, potentially larger deals focused on high-value…
- Pharmaceutical Commerce
Will Pharma M&A Slow Down This Year?
The article examines whether pharma M&A will slow in 2026, predicting continued dealmaking but potentially fewer, larger acquisitions than in 2025. With patent expirations and growth gaps driving demand, companies are expected to remain selective and prioritize high-value assets in areas like oncology, immunology and…
- Pharmaceutical Commerce
Patent Cliff Pressure to Sustain Pharma M&A Momentum in 2026
The article examines how the approaching patent cliff and persistent growth gaps are expected to sustain pharma M&A activity in 2026. Companies are likely to remain selective, targeting high-value, first- or best-in-class assets to strengthen pipelines and offset future revenue losses.
…- Investor's Business Daily
China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse
The article examines China’s rapid rise as a global biotech powerhouse, driven by growing R&D investment, faster development and advances in areas like oncology and next-generation therapies. As Chinese innovation attracts more global pharma partnerships and dealmaking, U.S. biotechs face increasing competition alongside new opportunities…
- pharmaphorum
European Biopharma at a Crossroads
The article examines Europe’s shifting position in global biopharma as investment and drug development increasingly move toward the U.S. and China. Despite declining funding and pipeline share, Europe remains strong in breakthrough innovation and could strengthen its global competitiveness through increased investment, regulatory modernization and…
- PharmaVoice
PharmaVoice’s Crystal Ball: What’s Next for AI and Drug R&D
The article explores pharma leaders’ predictions for AI and drug R&D in 2026, highlighting the growing role of agentic AI in drug discovery and clinical development, more efficient and adaptive trials, and advances in areas like oncology and CNS. Experts expect AI-driven insights, integrated datasets…
- PharmaVoice
PharmaVoice’s Crystal Ball: Market and Policy Forces Shaping the Industry
The article explores pharma leaders’ outlook for 2026, predicting a rebound in biopharma investment and M&A alongside faster FDA pathways, evolving pricing strategies and increased regulatory scrutiny. Experts also anticipate growth in areas like obesity treatments and greater pressure on companies to adapt their commercialization…
- Drug Discovery & Development
Pharma M&A, China Deals and GLP-1s: What to Watch in 2026
The article outlines key pharma trends to watch in 2026, including continued M&A momentum, surging dealmaking with Chinese biotechs and further growth in obesity treatments. Oral and combination GLP-1 therapies are expected to gain ground, while emerging oncology approaches such as ADCs, PD-1/VEGF bispecifics and…
- BioXconomy
BioXconomy’s Top 10 M&A Deals of 2025
The article highlights the 10 largest biotech M&A deals of 2025, as major pharma companies turned to acquisitions to strengthen pipelines ahead of looming patent expirations. Deals spanning neuroscience, obesity, oncology and rare diseases helped drive a rebound in M&A, with innovative biotechs becoming increasingly…
- Investor's Business Daily
These Three Catalysts Could Make Medical Stocks A Healthy Bet In 2026
The video explores the outlook for biotech and medical stocks in 2026, with Norstella’s Dan Chancellor highlighting next-generation obesity treatments, precision medicine and AI as three major catalysts for continued industry growth. Following biotech’s rebound in 2025, these areas could drive further innovation and investment…
- BioXconomy
Investment Crisis: AstraZeneca Halts $271m UK Expansion
The article examines AstraZeneca’s decision to pause a $271 million Cambridge expansion, completing the withdrawal of its planned $884 million UK investment package. Alongside similar moves by other pharma companies, the decision highlights concerns about limited government support, constrained healthcare spending and the UK’s declining…
- PharmaVoice
Could Bispecifics Unseat Keytruda From Its Oncology Throne?
The article explores the growing potential of bispecific antibodies to challenge Keytruda’s dominance in oncology, particularly therapies targeting both PD-1/PD-L1 and VEGF. While candidates like ivonescimab have shown promising results, Norstella’s Ethan Smith notes that clinical setbacks, a more fragmented oncology market and Keytruda’s broad…
- Bloomberg
China Biotech’s Stunning Advance is Changing the World’s Drug Pipeline
The article examines China’s rapid rise as a global biotech innovator, with its pipeline of novel drugs now approaching U.S. levels and surpassing Europe. Using Norstella data, Bloomberg highlights how faster development, regulatory reforms and increasingly sophisticated therapies are attracting Western pharma partnerships and shifting…
- MM+M
The Escalator: Norstella, WeightWatchers, Pfizer and More
The article highlights recent leadership moves across pharma and healthcare, including Norstella’s appointment of Nancy Phelan as president of its Commercial Solutions business. The roundup also covers executive appointments and departures at companies including WeightWatchers and Pfizer, reflecting ongoing leadership changes across the industry.
…- Yahoo! Finance
With ADCs on the Rise, Drugmakers Embrace a New Oncology Pillar
The article explores the rapid growth of antibody-drug conjugates (ADCs), which are becoming one of oncology’s most competitive areas as drugmakers pursue new targets, combinations and treatment settings. Strong clinical results and significant dealmaking are fueling investment in next-generation ADCs, positioning the technology to play…
- PharmaLive
Norstella’s Ethan Smith on Trends at ASCO 2025
The article highlights Norstella’s Ethan Smith’s key takeaways from ASCO 2025, including the growing role of antibody-drug conjugates (ADCs) as standards of care and the emergence of PD-(L)1/VEGF bispecific therapies. It also points to China’s expanding influence in oncology innovation, as Western pharma increasingly licenses…
- PharmaVoice
With ADCs on the Rise, Drugmakers Embrace a New Oncology Pillar
The article explores the rapid rise of antibody-drug conjugates (ADCs) as a major pillar of oncology, fueled by promising clinical data and advances in targeting and drug delivery. With treatments like Enhertu moving into earlier lines of care, drugmakers are investing heavily in next-generation ADCs…
- Labiotech
ASCO 2025: Key Highlights in Cancer Therapeutics
The article highlights key advances from ASCO 2025, where immunotherapies, antibody-drug conjugates and cell therapies dominated oncology research. Promising data across multiple cancers point toward more personalized, targeted treatment approaches, while emerging technologies such as AI-enabled clinical trials could further improve cancer drug development and…
- The i Paper
Own-Label ‘Ozempic’ Could Be as Cheap as £10 within Years
The article explores how upcoming patent expirations for semaglutide could open the door to much cheaper generic versions of drugs like Ozempic and Wegovy. Increased competition from generic manufacturers could dramatically reduce prices and expand access to GLP-1 treatments, potentially transforming the global weight-loss drug…
- BioXconomy
Going in Vivo: AstraZeneca Acquires EsoBiotec in Potential $1bn Deal
The article highlights AstraZeneca’s acquisition of EsoBiotec for up to $1 billion, expanding its investment in next-generation cell therapies. EsoBiotec’s in vivo CAR-T platform could simplify treatment by engineering immune cells directly inside patients, potentially overcoming manufacturing and accessibility challenges associated with traditional cell therapies.
…- Fast Company
The Most Innovative Data Science Companies of 2025
The article highlights Fast Company’s most innovative data science companies of 2025, including Norstella, which ranked No. 4 for using billions of data points to accelerate drug development. Norstella was recognized for combining real-world, clinical and commercial data with AI to improve clinical trial planning,…
- Medicine Maker
The Role of Data in Drug Development
The article explores how connecting data across the drug development lifecycle can help pharma improve R&D productivity, clinical trial planning and patient access. Norstella’s Daniel Chancellor highlights how integrating real-world, clinical and commercial data—and applying AI and predictive analytics—can help companies identify the right patients,…
- Precision Medicine Online
AI Offers Potential to Streamline Patient Screening for Precision Medicine Clinical Trials
AI is helping streamline patient screening and enrollment for precision medicine clinical trials by analyzing complex real-world data to identify eligible patients more efficiently. The article highlights how NorstellaLinQ can help sponsors and investigators match patients to increasingly specific trial criteria, reducing manual work and…
- Business Intelligence Group
Norstella Recognized as Company of the Year in the 2024 BIG Awards for Business
Norstella is pleased to announce that the Business Intelligence Group has selected the company as a winner in its hotly contested “Company of the Year” category. This recognition, part of the broader 2024 BIG Awards for Business, celebrates those companies, products, and leaders making a…
- STAT
These 6 Companies are Using AI to Streamline Clinical Trials for Pharma
Norstella is recognized as one of six companies using AI to help transform the design and execution of clinical trials. The article explores how AI and machine learning are helping life sciences organizations optimize trial processes, make better use of complex data and accelerate drug…
- Applied Clinical Trials
How Robust Data Technology is Transforming the Design and Execution of Viable Clinical Trials
Norstella and Citeline explore how real-world data, real-world evidence and advanced analytics can help life sciences organizations design and execute more effective clinical trials. The article highlights how a data-driven approach can improve patient recruitment, site selection and trial design while reducing delays and accelerating…
- pharma's almanac
What Do You View as the Most Disruptive or Transformational Technology or Development on the Horizon?
Norstella highlights the transformative potential of real-world data and evidence across the drug development lifecycle. The article explores how RWD can improve clinical trial design and recruitment, reduce investment risk, inform payer decisions and ultimately help accelerate patient access to therapies.
…- PharmaVoice
The 2023 PharmaVoice Crystal Ball: Peering into the Future of Life Sciences
The article explores key trends expected to shape the life sciences industry, from digital transformation and clinical trial innovation to evolving market and regulatory pressures. Norstella CEO Mike Gallup highlights the need to overcome barriers that slow drug development and patient access, emphasizing the importance…
- MM+M
Industry Leaders Offer Reflections on 2022 and Predictions for 2023
The article explores key trends shaping medical marketing, with industry leaders reflecting on 2022 and looking ahead to 2023. It highlights the growing importance of data, technology and more personalized strategies to help life sciences organizations better understand and engage patients and healthcare professionals.
…- HealthIT Answers
What Can We Expect in Pharma in 2023?
The article explores key trends expected to shape the pharmaceutical industry, including drug pricing, clinical trial innovation, AI and real-world data. MMIT and Panalgo experts highlight how biosimilars could improve patient access and how real-world data and analytics can support more diverse, effective clinical trials…
- Fierce Biotech
Norstella Completes Acquisition of Citeline to Form $5B Pharma Intelligence Group
The article highlights Norstella’s acquisition of Citeline, creating a $5 billion pharmaceutical intelligence group with more than 1,600 employees. The combined organization brings together clinical, commercial, market access and real-world data expertise to help life sciences companies identify unmet needs, improve clinical trial design and…
- pharmaphorum
Norstella, Citeline Merge to Create $5bn Pharma Tech Firm
The article highlights the merger of Norstella and Citeline, creating a $5 billion pharmaceutical intelligence and technology company. By combining data, analytics and expertise across the drug development lifecycle, the organization aims to help life sciences companies make more informed decisions, navigate complex patient and…
- Drug Discovery World
Merger Creates $5 Billion Pharma Technology Company
The article highlights the merger of Norstella and Citeline, creating a $5 billion global pharmaceutical technology company and one of the world’s largest pharma intelligence providers. The combined organization brings together data, analytics and expertise across the drug development lifecycle to help life sciences companies…
- Philadelphia Business Journal
Norstella Completes Merger with Citeline to Form $5B Pharma Tech Company
The article highlights the merger of Norstella and Citeline, creating a $5 billion pharmaceutical technology company with more than 1,500 employees worldwide. It explores how the combined organization brings together data, intelligence and technology to support life sciences companies throughout the drug development lifecycle and…
- MM+M
Citeline, Norstella Complete $5B Merger
The article highlights the completion of the $5 billion merger between Norstella and Citeline, creating one of the world’s largest pharmaceutical intelligence solutions providers. The combined organization brings together clinical, commercial, market access and real-world data capabilities to help life sciences companies make better decisions…
Events
- Conference
- August 2026
ISPE
- Conference
- September 2026
Fierce Pharma Week
- Conference
- October 2026
AMCP Nexus
- Conference
- November 2026
ISPOR EU
Press Releases
Norstella Launches Capsul, a Free Daily Intelligence Brief for the Pharma and Biotech Industry
Norstella Launches Atlas, an Agentic AI Platform Built on Biopharma’s Most Connected Data
Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development Lifecycle
Evaluate Recognized for Artificial Intelligence Innovation in 9th Annual AI Breakthrough Awards Program
Recursion Expands Strategic Partnership with Citeline to Advance its AI-Enabled ClinTech Platform
The Full Picture of
Drug Development
Follow Norstella to clear the hurdles from pipeline to patient.
